USA flag logo/image

An Official Website of the United States Government

Development of an adipose-derived stem cell isolation matrix

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96213
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
GM093462
Solicitation Year:
N/A
Solicitation Topic Code:
NIGMS
Solicitation Number:
N/A
Small Business Information
AFFINERGY ,INC
BOX 14650, 617 DAVIS DR STE 100 RESEARCH TRIANGLE PARK, NC -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Development of an adipose-derived stem cell isolation matrix
Agency: HHS
Contract: 1R43GM093462-01
Award Amount: $308,237.00
 

Abstract:

DESCRIPTION (provided by applicant): Mesenchymal stem cells (MSCs) are an adult stem cell population, typically isolated from bone marrow aspirates, and are capable of self-renewal, expansion in culture, and differentiation into adipocytes, chondrocytes, a nd osteoblasts. These cells are being explored for use in tissue engineering applications, such as spinal fusions, bone defect repairs, and cartilage regeneration. In general, to attain cell numbers required for these applications, the cells are typically expanded in culture over a number of passages; however, the ex vivo expansion of these cells has been shown to induce changes in gene expression and affect the ability of these cells to differentiate. This suggests that the use of MSCs as a therapeutic wou ld be most efficacious with high numbers of freshly isolated cells, but would require impractical amounts of bone marrow to be feasible. Adipose derived stem-cells (ASCs) have been proposed as an alternative to bone marrow-derived MSCs in several clinical indications. These cells are estimated to be 500-fold more abundant per gram of adipose tissue compared to the number of MSCs in a similar mass of bone marrow. Furthermore, adipose tissue is more abundant and more easily obtained with less patient morbidit y than bone marrow. Therefore, we hypothesize that the development of an ASC enrichment system would allow for point-of-care isolation of large numbers of autologous cells, thereby eliminating the need for ex vivo expansion prior to implantation. In this p roposal, we will employ our core platform technology-phage display biopanning-to identify an ASC-binding peptide and test its ability to isolate these adult stem cells from adipose tissue. In parallel research programs, we have identified peptides capable of isolating MSCs from bone marrow aspirate preparations with minimal cross-reactivity with other cell types, thereby validating the approach of this proposal. We will first identify ASC-binding peptides using phage display, then couple the peptides to a r esin. This peptide-coated matrix will be used for the optimization of ASC binding and elution conditions using cultured cells and to enrich ASCs from the crude cellular fraction of lipoaspirates. Finally, we will characterize the ASC surface markers and th eir ability to differentiate into three lineages to ensure that exposure to our peptide did not affect the stem-like qualities of these cells. Based on our results with MSC isolation, we envision that a product consisting of a solid support matrix coupled to our ASC-binding peptide would allow for the isolation of autologous ASCs-a cell population that is more easily accessible and abundant than that of bone marrow-for point-of-care therapeutic use. PUBLIC HEALTH RELEVANCE: Adult stem cells are begin ning to appear in new medical products. Typically, these cells are mesenchymal stem cells derived from bone marrow. However, their low numbers in bone marrow require the cells to be isolated and expanded ex vivo prior to their incorporation into a marketed product. Here, we seek to develop a novel stem cell-binding reagent to harvest stem cells from adipose tissue. Adipose-derived stem cells are far more numerous than those derived from bone marrow. This increase could potentially enable point-of-care use o f adipose-derived stem cells, allowing a surgeon to harvest and deploy cells from autologous sources in a surgical procedure. We currently envision this peptide-based reagent to be used in a culture-free method of ASC isolation prior to their use in tissue engineering applications.

Principal Investigator:

Martyn Darby
2159554504

Business Contact:

Chris Brasfield
jgindes@affinergy.com
Small Business Information at Submission:

AFFINERGY ,INC
PO BOX 14650 RESEARCH TRIANGLE PARK, NC 27709

EIN/Tax ID: 155082607
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No